"As we prepare for the establishment of the Group, we are cognisant of the inherent risks of such a broad reaching reform agenda and the need to balance this with the need for reform to speed up patient access to new medicines," said chief executive Liz de Somer.
Medicines Australia strikes cautious tone on HTA review implementation group
October 2, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
TGA approves first-of-a-kind medicine for early symptomatic Alzheimer’s disease
May 21, 2025 - - Latest News -
Examples are important as evidence of the problem, but be prepared to defend them
May 21, 2025 - - Latest News -
Trump administration invites companies to 'align' US pricing under MFN plan
May 21, 2025 - - Latest News -
NDIS minister restates the importance of 'nothing about us, without us!'
May 20, 2025 - - Latest News -
Industry alarm over the sudden pursuit of surprise uncertified claims
May 20, 2025 - - Latest News -
Medicines Australia sharpens post-election language on reform
May 20, 2025 - - Latest News -
Report highlights international confidence in Australian clinical trials
May 19, 2025 - - Latest News